pubmed.ncbi.nlm.nih.gov

Pediatric oncology drug development and dosage optimization - PubMed

  • ️Mon Jan 01 2024

Review

Pediatric oncology drug development and dosage optimization

S Y Amy Cheung et al. Front Oncol. 2024.

Abstract

Oncology drug discovery and development has always been an area facing many challenges. Phase 1 oncology studies are typically small, open-label, sequential studies enrolling a small sample of adult patients (i.e., 3-6 patients/cohort) in dose escalation. Pediatric evaluations typically lag behind the adult development program. The pediatric starting dose is traditionally referenced on the recommended phase 2 dose in adults with the incorporation of body size scaling. The size of the study is also small and dependent upon the prevalence of the disease in the pediatric population. Similar to adult development, the dose is escalated or de-escalated until reaching the maximum tolerated dose (MTD) that also provides desired biological activities or efficacy. The escalation steps and identification of MTD are often rule-based and do not incorporate all the available information, such as pharmacokinetic (PK), pharmacodynamic (PD), tolerability and efficacy data. Therefore, it is doubtful if the MTD approach is optimal to determine the dosage. Hence, it is important to evaluate whether there is an optimal dosage below the MTD, especially considering the emerging complexity of combination therapies and the long-term tolerability and safety of the treatments. Identification of an optimal dosage is also vital not only for adult patients but for pediatric populations as well. Dosage-finding is much more challenging for pediatric populations due to the limited patient population and differences among the pediatric age range in terms of maturation and ontogeny that could impact PK. Many sponsors defer the pediatric strategy as they are often perplexed by the challenges presented by pediatric oncology drug development (model of action relevancy to pediatric population, budget, timeline and regulatory requirements). This leads to a limited number of approved drugs for pediatric oncology patients. This review article provides the current regulatory landscape, incentives and how they impact pediatric drug discovery and development. We also consider different pediatric cancers and potential clinical trial challenges/opportunities when designing pediatric clinical trials. An outline of how quantitative methods such as pharmacometrics/modelling & simulation can support the dosage-finding and justification is also included. Finally, we provide some reflections that we consider helpful to accelerate pediatric drug discovery and development.

Keywords: Project Optimus; clinical trial design; dosage optimization; model informed drug development; modeling and simulation; oncology; pediatric.

Copyright © 2024 Cheung, Hay, Lin, de Greef and Bullock.

PubMed Disclaimer

Conflict of interest statement

All authors are employees of Certara and own shares of Certara.

Figures

Figure 1
Figure 1

Challenge and opportunities when considering oncology pediatric drug development. Abbreviations: model informed drug development (MIDD), chemotherapies (CTx), radiotherapies (RTx), standard of care (SoC), chimeric antigen receptor T-cell (CAR-T) therapy, IMI ITCC-P4 (ITCC pediatric preclinical POC platform).

Similar articles

References

    1. American Cancer Society . Key statistics for childhood cancers (2023). Available at: https://www.cancer.org/cancer/types/cancer-in-children/key-statistics.html.
    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol (2009) 27(17):2758–65. doi: 10.1200/jco.2008.20.8983 - DOI - PubMed
    1. Jemal AT L, Soerjomataram I, Bray F. eds. The burden of cancer. In: The cancer atlas, 3rd. Atlanta,. GA: American Cancer Society. p. 136.
    1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. . (eds). SEER Cancer Statistics Review, 1975–2017. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
    1. Lee CE, Singleton KS, Wallin M, Faundez V. Rare genetic diseases: nature’s experiments on human development. iScience (2020) 23(5):101123. doi: 10.1016/j.isci.2020.101123 - DOI - PMC - PubMed

Publication types

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

LinkOut - more resources